According to UCB, Nayzilam midazolam nasal spray will be available in the US as of December 2, 2019. UCB acquired the nasal spray from Proximagen in April 2018, and the FDA approved Nayzilam for the treatment of seizure clusters in epilepsy patients 12 years old and older in May 2019.
The company said that Nayzilam is expected to cost $40 for a box containing two doses. A savings card provided by the company could reduce the cost to $20 per box.
UCB US Head of Neurology Mike Davis said, “Delivering another of the six potential new product launches, a UCB mission over the next five years, Nayzilam builds on UCB’s commitment to addressing the unmet needs of people living with epilepsy. For the first time, people 12 years and older now have a nasally administered rescue therapy shown to help manage seizure clusters. Nayzilam can be administered anywhere seizure clusters strike, allowing families to take back valuable moments that would otherwise be lost.”
Read the UCB press release.
